📰 Resented News
Page 29 - Resented News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Resented. Real-time updates on events, politics, business and more.
January 12, 2023
Granite has been listed by Newsweek as one of America’s Most Responsible Companies in 2023. This important recognition is presented by Newsweek and Statista Inc., the world-leading statistics... | January 12, 2023
January 12, 2023
Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023
January 10, 2023
WEST PALM BEACH, Fla., Jan. 10, 2023, the official brand of the United States Polo Association (USPA), the governing body for the sport of polo in the United States. The original agreement, signed
January 4, 2023
The Portuguese superstar was presented to fans at Al Nassr on Tuesday Cristiano Ronaldo made a slip of the tongue as he was presented to t
December 22, 2022
Bedminster, NJ, Dec. 22, 2022 -- via NewMediaWire -- This holiday season, Peapack-Gladstone Bank presented its 2nd Annual Boonton Christmas Tree Sale to benefit charity. Held... | December 22, 2022
December 21, 2022
Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical
December 20, 2022
RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GvHD REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative
December 11, 2022
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia
December 10, 2022
The findings of IPAN's groundbreaking "people's inquiry", examining Australia's defence policy and involvement in U.S.-led wars,&n
December 10, 2022
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR